Investors sentiment increased to 1.29 in Q4 2018. Its up 0.18, from 1.11 in 2018Q3. It improved, as 17 investors sold Coherus BioSciences, Inc. shares while 25 reduced holdings. 22 funds opened positions while 32 raised stakes. 59.12 million shares or 0.82% less from 59.61 million shares in 2018Q3 were reported.
Ameriprise Fincl holds 518,118 shares or 0% of its portfolio. Aqr Cap Limited Liability Company accumulated 39,425 shares or 0% of the stock. Royal Bancorporation Of Canada has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Sectoral Asset Management owns 27,987 shares. Savings Bank Of America De invested 0% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS). Wellington Mgmt Limited Liability Partnership holds 0.02% or 7.66 million shares. Dekabank Deutsche Girozentrale stated it has 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). 83,178 were accumulated by Morgan Stanley. Ameritas Prtn reported 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Federated Incorporated Pa holds 0% or 1,348 shares. Jpmorgan Chase reported 0.01% of its portfolio in Coherus BioSciences, Inc. (NASDAQ:CHRS). D E Shaw & Inc has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Highland Cap L P, a Texas-based fund reported 230,125 shares. Macquarie Group Inc Limited stated it has 430,300 shares. Fincl Bank Of Montreal Can holds 737 shares or 0% of its portfolio.
The stock of Coherus Biosciences Inc (NASDAQ:CHRS) registered a decrease of 7.19% in short interest. CHRS’s total short interest was 9.12M shares in May as published by FINRA. Its down 7.19% from 9.82 million shares, reported previously. With 613,400 shares average volume, it will take short sellers 15 days to cover their CHRS’s short positions. The short interest to Coherus Biosciences Inc’s float is 17.95%.
The stock increased 8.51% or $1.37 during the last trading session, reaching $17.47. About 1.43M shares traded or 73.04% up from the average. Coherus BioSciences, Inc. (NASDAQ:CHRS) has risen 53.37% since May 11, 2018 and is uptrending. It has outperformed by 49.00% the S&P500.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company has market cap of $1.21 billion. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. It currently has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, BehÃ§et’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage
Among 2 analysts covering Coherus Biosciences (NASDAQ:CHRS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Coherus Biosciences had 3 analyst reports since March 1, 2019 according to SRatingsIntel. The firm has “Buy” rating given on Friday, March 1 by Maxim Group. The company was maintained on Thursday, March 7 by Credit Suisse.
More notable recent Coherus BioSciences, Inc. (NASDAQ:CHRS) news were published by: Seekingalpha.com which released: “Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” on November 08, 2018, also Seekingalpha.com with their article: “Coherus settles Humira patent dispute with AbbVie – Seeking Alpha” published on January 25, 2019, Globenewswire.com published: “Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results – GlobeNewswire” on February 28, 2019. More interesting news about Coherus BioSciences, Inc. (NASDAQ:CHRS) were released by: Seekingalpha.com and their article: “Coherus BioSciences’ (CHRS) CEO Dennis Lanfear on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” published on August 08, 2018 as well as Nasdaq.com‘s news article titled: “Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer – Nasdaq” with publication date: March 18, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.